THE HIGHEST CONCENTRATION of IGFs is in the blood, where the IGFs are present mainly as a 150-kDa ternary complex composed of IGF, IGF-binding protein (IGFBP)-3, and an acid-labile subunit. This complex prolongs the half-life of IGF-I and IGF-II in the blood, presumably because the 150-kDa complex does not easily cross the endothelial boundary to sites of IGF action. The endocrine role of the circulating IGFs and the mechanism(s) whereby IGFs traverse the endothelium have not been defined clearly (4, 6) .
In the present report, we have used the isolated, beating rat heart to study the transendothelial transport of the perfused binary IGF ⅐ IGFBP-3 complex. The isolated rat heart was chosen because its perfused surface is Ն99% microvessels, the capillaries have tight interendothelial junctions, the preparation requires small perfused volumes, and the capillary endothelium has distinct and specific binding sites for IGF-I.
We demonstrate the presence of IGFBP-3 binding sites in the perfused heart and examine the roles of IGFBP-3 and the IGF-I binding sites in the transport of perfused IGF-I to cardiac muscle.
MATERIALS AND METHODS
Cell binding. Microvessel endothelial cells were prepared from bovine heart adipose tissue, as previously described (9) . In vitro binding studies were performed with confluent microvessel cells on 12-well Linbro trays (ICN, Aurora, OH). 125 I-labeled IGF-I or 125 I-IGFBP [2 ϫ 10 4 counts/min (cpm)] was added to 12-well trays alone or with unlabeled IGFs or IGFBPs. After 90 min at 22°C, the monolayer was removed with 0.1 N NaOH and counted in a gamma counter. Data are expressed as means Ϯ SE in three wells. Each experiment was performed three times.
Preparation of chimeric IGFBP-4 3 and IGFBP-34. The basic COOH-terminal 20 amino acids of IGFBP-3 (P3 region) and the homologous domain of IGFBP-4 (P4 region) were "swapped out" to generate the IGFBP-4 3 and IGFBP-34 chimeras, as previously described (9) . The genes encoding the chimeric binding proteins were excised from the cloning vector and ligated into the EcoRI/XhoI sites of the vector pBacPAK9 (Clontech, Palo Alto, CA) for the expression and production of the chimeric IGFBPs in a baculovirus system. IGFBP-4 3 and IGFBP-34 were purified from media of infected High-Five insect cells.
Heart perfusion. Adult male Sprague-Dawley rats, weighing ϳ300 g (Harlan Sprague Dawley, Indianapolis, IN), were anesthetized, the chest cavities opened, and the hearts removed and suspended by a perfusion catheter placed in the aorta. Perfusions were done for 1 min at a flow rate of 3 ml/min. The hearts were perfusion fixed, embedded in paraffin, and prepared for autoradiography as previously described (2, 9). After 6-10 wk, the sections were developed, and the number of silver grains overlying subluminal cardiac muscle was assessed. For consistency, counts were done in the outer region of the midportion of the left ventricle, near large arteries where perfusion is optimal. Data are expressed as the number of grains per unit area. All animal studies were approved by the Veterans Affairs and University of Iowa Animal Care Committees.
RESULTS
We used several agents to identify the presence of specific binding sites for IGFBP-3 in the perfused heart.
125 I-IGFBP-3 and -IGFBP-4 3 , both of which have been shown to bind specifically to cultured microvessel endothelial cells (5, 9) , were perfused through the hearts. IGFBP-4 3 is a chimera of IGFBP-4 in which a 20-amino acid basic COOH-terminal portion of IGFBP-4 has been "swapped" with the homologous region of IGFBP-3. IGFBP-4 3 , like IGFBP-3, binds to cultured microvessel endothelial cells with high affinity.
125
I-IGFBP-3 4 and -IGFBP-4 were tested in the perfused heart, because neither binds well to cultured microvessel endothelial cells (5, 9), whereas both bind to IGF-I with high affinity. Each 125 I-IGFBP (3, 4 3 , 4, and 3 4 ) was perfused through beating hearts (n ϭ 3) and counted for 125 I grains (Fig. 1) . As in cultured cells, hearts perfused with IGFBP-3 and IGFBP-4 3 retained a substantial number of 125 I grains, whereas hearts perfused with IGFBP-4 and IGFBP-3 4 retained Ͻ15% of that contained in hearts perfused with IGFBP-3 or -4 3 (Fig. 1) .
These findings suggest that the perfused heart, as well as cultured microvessel endothelial cells, has specific binding sites for both IGF-I and for IGFBP-3. We next examined the potential roles of each binding site in the transendothelial transport of perfused IGF-I and the perfused binary complex of IGFBP-3 ⅐ IGF-I. It has been previously shown that both perfused IGF-I and IGFBP-3 cross the endothelial boundary and localize predominantly in cardiac muscle (1 
DISCUSSION
The isolated beating rat heart contains specific microvessel binding sites for IGF-I and responds to IGF by modulating glucose metabolism and lactic acid production. We demonstrate that the beating rat heart also has specific binding for IGFBP-3 and that these binding sites may contribute to the transport of IGF-I to cardiac muscle, the presumed target of IGF-I bioactivity in the heart. The presence of IGF binding sites was demonstrated by perfusion of hearts with IGFBP-3, -4 3 , -4, and -3 4 . IGFBP-4 3 binds to cultured endothelial cells with equal to or higher affinity than IGFBP-3. It acquires this property even though most of its structure is identical to IGFBP-4, which does not bind to endothelial cells. In contrast, IGFBP-3 4 , primarily IGFBP-3 in structure, binds weakly to cultured endothelial cells. When perfused through the heart, IG-FBP-3 and IGFBP-4 3 were retained in the hearts, whereas IGFBP-4 and IGFBP-3 4 were minimally retained.
The concept of the IGF-I binding sites and IGFBP-3 sites playing a role in the transport of perfused IGF-I to underlying cardiac muscle was suggested in several ways. For IGF-I receptors, when 125 I-IGF-I was first perfused by itself, substantial IGF-I was transported to cardiac muscle. The same study was repeated with the addition of LR 3 IGF-I, an IGF-I analog known to block IGF-I receptors. This decreased the appearance of IGF-I in cardiac muscle to ϳ10% of that with perfusion of 125 I-IGF-I alone. We next examined the potential role of the IGFBP-3 binding sites in the transport of perfused IGF-I. When 125 I-IGF-I was perfused as the binary complex IGF-I ⅐ IGFBP-3 in a molar ratio of IGF-I to IGFBP-3 of 1:10, transport was decreased to 84% of IGF-I alone, which was not statistically different from perfusion with IGF-I alone. When IGF-I binding sites were blocked by the addition of LR 3 IGF-I, transport of IGF-I in the presence of IGFBP-3 was decreased to 41% of IGF-I alone, which was significantly more than perfusion with IGF-I plus similar concentrations of LR 3 IGF-I (41 vs. 10%). This suggested that the IGFBP-3 can chaperone IGF-I through the IGFBP-3 binding sites. However, it should be noted that, in cultured endothelial cells, 125 I-IGF-I ⅐ IGFBP-3 complexes at a 1:10 ratio, a similar ratio as in the perfused hearts, bound minimally to the IGF-I receptors, suggesting that binary complexes in the beating heart may behave differently than when exposed to cultured cells. 1 Free IGF-I and IGF-I ⅐ IGFBP-3 binary complexes are present in the circulation (10) , and the binary complex has been used in therapy (7) . However, Ͼ90% of all IGF-I in the blood is contained in the ternary complex of IGF-I ⅐ IGFBP-3/acid-labile subunit (4) . If free IGF-I and the binary complex of IGF-I ⅐ IGFBP-3 are the only forms of IGF-I that do cross the endothelial boundary, then results of the present study are obviously relevant. However, if IGF-I in the ternary complex does have an endocrine function, then the mechanisms whereby IGF-I or IGF-I ⅐ IGFBP-3 is freed from the 150-kDa complex need to be defined to better understand the mechanisms and control of such processes in understanding the normal and pathological physiology of IGF.
